Home > Investors
Investor Relations Home
E-mail Page Print Page RSS Feeds E-mail Alerts IR Contacts Financial Tear Sheet 
About Us
Download Documentation 2016 Guidance Worksheet
Download Documentation ALN-PCSsc Phase 1 Clinical Results Presentation
Download Documentation Update on ABP-700
Download Documentation ALN-PCSsc Phase 1 Clinical Results Presentation
Download Documentation ABP-700 & MDCO-216 Conference Call Presentation
Corporate Profile
The Medicines Company provides medical solutions to improve health outcomes for patients in acute and intensive care hospitals worldwide. These solutions comprise medicines and knowledge that directly impact the survival and well-being of critically ill patients.
Stock Quote
MDCO (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Up 0.10 (0.27%)
Data as of 01/19/17 9:30 a.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
01/08/17The Medicines Company Announces Positive Top-Line Results from Day 180 Interim Analysis in Ongoing ORION-1 Phase 2 Study of Inclisiran (formerly, PCSK9si)
Compelling safety and efficacy data from Day 180 interim analysis Inclisiran continued to demonstrate significant and durable LDL-C reduction, reaffirming the potential for a highly-differentiated dosing regimen of two or three injections per year Inclisiran continued to demonstrate high standards of safety and tolerability The Medicines Company reinforces its commitment to advancing the development of inclisiran with initi... 
Printer Friendly Version
01/04/17The Medicines Company to Present at J. P. Morgan Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jan. 4, 2017-- The Medicines Company (Nasdaq: MDCO) today announced that its Chief Executive Officer, Clive Meanwell, M.D., Ph.D., will present at the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2017, at 7:30 a.m., Pacific time. A live audio webcast of the presentation will be available in the “Investors” section of The Medicines Company website, www.themedicinescompany.com, ... 
Printer Friendly Version
11/15/16The Medicines Company and Alnylam Pharmaceuticals Present Positive Results from ORION-1 Phase 2 Study of Inclisiran (formerly PCSK9si)
—Study meets all interim analysis goals— —A single injection of inclisiran (300 mg) lowered ‘bad cholesterol’ (LDL-C) by an average of 51%, and up to 76%— —Two injections of inclisiran (300 mg) lowered LDL-C by an average of 57% and up to 81%— —Significant LDL-C reductions were sustained out to 180 days following a single dose— —Potential for highly-differentiated, infrequent, low volume dosing regimen of 2 o... 
Printer Friendly Version
11/13/16Alnylam Pharmaceuticals and The Medicines Company Announce Publication of Phase 1 Clinical Data with Inclisiran (ALN- PCSsc) in the New England Journal of Medicine
Interim Results from ORION-1 Phase 2 Study of Inclisiran to be Presented in Late-Breaking Clinical Trial Session at the American Heart Association Scientific Sessions on November 15, 2016 CAMBRIDGE, Mass. & PARSIPANY, N.J.--(BUSINESS WIRE)--Nov. 13, 2016-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, and The Medicines Company (Nasdaq:MDCO), a leading biopharmaceutical development and cardi... 
Printer Friendly Version
Upcoming Events
There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.